AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Apr 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-04-02

Reporting Person: Schenkein David P (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-02	Common stock	M	13000	$0.3025	Acquired	13000	Direct
2018-04-02	Common stock	S	1557	$75.54	Disposed	11443	Direct
2018-04-02	Common stock	S	2600	$76.40	Disposed	8843	Direct
2018-04-02	Common stock	S	3340	$77.76	Disposed	5503	Direct
2018-04-02	Common stock	S	3390	$78.59	Disposed	2113	Direct
2018-04-02	Common stock	S	2113	$79.49	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-02	Stock option (right to buy)	$0.3025	M	13000	Disposed	2019-08-12	Common stock (13000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	271772	Indirect
Common stock	79082	Indirect

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.00 to $75.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.02 to $77.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.10 to $78.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.11 to $79.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F7: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.16 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F8: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.

F9: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.

F10: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.